Cargando…
Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
Heart failure is an important manifestation of diabetic heart disease. Before the development of symptomatic heart failure, as much as 50% of patients with type 2 diabetes mellitus (T2DM) develop asymptomatic left ventricular dysfunction including left ventricular hypertrophy (LVH). Left ventricular...
Autores principales: | Mohan, Mohapradeep, Dihoum, Adel, Mordi, Ify R., Choy, Anna-Maria, Rena, Graham, Lang, Chim C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513785/ https://www.ncbi.nlm.nih.gov/pubmed/34660744 http://dx.doi.org/10.3389/fcvm.2021.746382 |
Ejemplares similares
-
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
por: Peh, Zhen Hui, et al.
Publicado: (2023) -
Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
por: Mordi, Natalie A, et al.
Publicado: (2017) -
A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial
por: Mohan, Mohapradeep, et al.
Publicado: (2019) -
Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
por: Singh, Jagdeep S. S., et al.
Publicado: (2016) -
Plasma desmosine for prediction of outcomes after acute myocardial infarction
por: Ali, Kashan, et al.
Publicado: (2022)